Adimanebart clinical trials
How each study uses adimanebart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the adimanebart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test adimanebart.
- Dec 2026A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult ParticipantsPhase 1 · argenx
- Aug 2027A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)Phase 1 · argenx
Studies
Open first, then newest update. How each study uses adimanebart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)Not yet recruitingPhase 3argenxNCT07746089Written as Adimanebart IV
- A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular AtrophyRecruitingPhase 2argenxNCT07287982Written as ARGX-119 IV
- A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult ParticipantsRecruitingPhase 1argenxNCT07673601Written as Adimanebart IV
- A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)TerminatedPhase 2argenxNCT06441682Written as ARGX-119
- A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)Active, not recruitingPhase 1argenxNCT06436742Written as ARGX-119
- A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy ParticipantsCompletedPhase 1argenxNCT05670704Written as ARGX-119
Codes
What other systems call adimanebart · ClinicalTrials.gg INT016565
- UNII (FDA) FJK85PF3WYADIMANEBARTOne source FDA
- NCI Thesaurus C215725AdimanebartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FJK85PF3WY | ADIMANEBART | One source FDA |
| NCI Thesaurus | C215725 | Adimanebart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.